Bausch & Lomb Corp (BLCO): Results of Operations and Financial Condition
Bausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q2-2026.htm EX-99.1 Document Exhibit 99.1 Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance • Revenue of $1.394 Billion • Revenue Grew 9% as Reported and 8% on a Constant Currency 1 Basis Compared to the Second Quarter of 2025
How this was made
The 30-second read
Why it matters
Q2 showed broad-based segment growth (Vision Care, Surgical, Pharmaceuticals), improved operating income, and a large jump in cash flow from operations. The company also raised FY 2026 revenue and adjusted EBITDA excluding acquired IPR&D ranges, which can drive near-term estimate revisions and multiple expansion if investors trust the three-year plan execution.
Market read
A quantified earnings and guidance update with segment detail and cash-flow improvement is actionable for reforecasting BLCO’s FY 2026 trajectory.
What to watch
The guidance includes constant-currency growth and FX tailwinds; traders may discount the reported ranges if FX reverses or if premium IOL and dry-eye brands face competitive pressure.
Background
This is an SEC Form 8-K (Item 2.02) reporting Q2 2026 results and updating full-year 2026 guidance for Bausch + Lomb.
Ticker impact
Bausch + Lomb reported Q2 2026 revenue of $1.394B (+9% reported) and raised full-year 2026 revenue and adjusted EBITDA guidance.
Likely near-term positive bias as traders reprice FY 2026 revenue and adjusted EBITDA expectations.
The filing is a primary 8-K with quantified Q2 results and explicit updated FY 2026 ranges, which typically drives immediate estimate revisions.
Market effects
Eye-care peers may see read-across on demand durability in contact lenses and branded dry-eye therapeutics, but impact is likely limited to sentiment.
No specific regional macro driver cited beyond constant-currency framing and FX tailwind disclosure.
International pharmaceuticals growth and FX-adjusted results highlight global demand resilience, relevant for multinational healthcare positioning.
Counterpoint
Despite guidance increases, GAAP net loss persists and adjusted metrics exclude acquired IPR&D, so quality of earnings and sustainability may be questioned.
Key entities
- issuerBausch + Lomb Corporation
Reported Q2 2026 financial results and raised full-year 2026 guidance in an 8-K.
- executiveBrent Saunders
CEO/Chairman quoted on progress versus the company’s three-year growth plan.
